provider portal
Wesper Journal
Wesper is poised to change sleep medicine alongside GLP-1 by integrating advanced sleep monitoring technology with GLP-1 therapies, enabling comprehensive and personalized treatment for sleep apnea. This combination offers real-time treatment optimization and enhanced patient outcomes, marking a significant advancement...
Continue reading
GLP-1 Receptor Agonists and Obstructive Sleep Apnea (OSA): A New Era in Sleep Health ManagementThe approval of GLP-1 receptor agonists, such as Zepbound (tirzepatide), represents a groundbreaking development in the treatment of Obstructive Sleep Apnea (OSA). These medications not only...
Continue reading
In a landmark move, the FDA approved Zepbound (tirzepatide), the first GLP-1-based medication for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, offering hope beyond traditional CPAP therapy. It works by activating GLP-1 and GIP hormone...
Continue reading
This in-depth interview with Dr. Atul Malhotra explores the clinical advantages of longitudinal sleep monitoring over single-night studies. The article covers emerging metrics like hypoxic burden, the importance of central sleep apnea detection, racial bias in pulse oximetry, and how GLP-1 therapies like tirzepatide are transforming obstructive sleep apnea treatment. Learn how Wesper’s airflow-based home testing platform delivers accurate, equitable, and evolving care for patients with sleep-disordered breathing.
Continue reading
This article explores how oral GLP-1 therapy, specifically Eli Lilly’s investigational pill orforglipron, may transform the treatment of obstructive sleep apnea (OSA) by targeting one of its primary root causes: obesity. It highlights clinical evidence from GLP-1 drugs like tirzepatide (Zepbound), which has already gained FDA approval for OSA, and examines how weight loss through these therapies significantly improves apnea severity. The article also outlines why the upcoming oral formulation is a game-changer, increasing accessibility and adherence for patients. With obesity, diabetes, and OSA deeply intertwined, GLP-1 therapy may soon play a central role in holistic sleep medicine.
Continue reading
